NEW YORK, April 29, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding General Motors Company (NYSE: GM), The Procter and Gamble Company (NYSE: PG), The Coca-Cola Company (NYSE: KO), Ford Motor Company (NYSE: F) and Mead Johnson Nutrition Company (NYSE: MJN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1751-100free.

--
General Motors Company Analyst Notes
On April 24, 2014, General Motors Company (GM) released Q1 2014 earnings, which were dented by recall charges and special items. Net revenue in Q1 2014 was $37.4 billion, compared to $36.9 billion in Q1 2013. Net income attributable to common stockholders was $125 million, or $0.06 per diluted share, versus $865 million, or $0.58 per diluted share in Q1 2013. According to GM, strong core operating performance during the quarter was more than offset by a net loss from special items of $0.4 billion, or $0.23 per diluted share, and a $1.3 billion pre-tax charge primarily for the cost of recall-related repairs, or $0.48 per diluted share. During the quarter, the Company's worldwide retail sales were up 2.3% YoY to 2.4 million vehicles. The full analyst notes on GM are available to download free of charge at:

http://www.analystsreview.com/1751-GM-29Apr2014.pdf

--
The Procter and Gamble Company Analyst Notes
On April 23, 2014, The Procter and Gamble Company (P&G) released its Q3 FY 2014 (period ended March 31, 2014). The Company reported Q3 FY 2014 net sales of $20.56 billion, down marginally by 0.2% YoY. The Company recorded organic sales growth of 3% in Q3 FY 2014. During the quarter, the Company's Fabric Care & Home Care segment sales improved 2% YoY to $6.3 billion, while sales in the grooming segment fell 4% to $1.9 billion. Q3 FY 2014 net earnings attributable to P&G came in at $2.6 billion or $0.90 per diluted share, compared to net income of $2.6 billion or $0.88 per diluted share. The Company's Q3 FY 2014 adjusted EPS came in at $1.04 beating the Zacks consensus estimate of $1.02. For full-year FY 2014, the Company expects organic sales growth between 3% to 4% and reported EPS growth in the range of 1%-4%. The full analyst notes on P&G are available to download free of charge at:

http://www.analystsreview.com/1751-PG-29Apr2014.pdf

--
The Coca-Cola Company Analyst Notes
On April 24, 2014, The Coca-Cola Company (Coca-Cola) announced that the Company's Board of Directors has elected Kathy N. Waller as Executive Vice President and CFO, with immediate effect. The Company previously made an announcement in February 2014, that Waller will succeed Gary Fayard who is retiring from the Company. Waller was previously working with Deloitte. In addition, the Board has also elected Larry M. Mark, Mark Randazza, Dr. Wamwari Waichungo, Ronald J. Lewis and Jos Wellekens as Vice Presidents of the Company, effective immediately. The Coca-Cola Board has also declared a quarterly dividend of $0.305 per common share, payable on July 1, 2014, to shareowners of record as of June 16, 2014. The full analyst notes on Coca-Cola are available to download free of charge at:

http://www.analystsreview.com/1751-KO-29Apr2014.pdf

--
Ford Motor Company Analyst Notes
On April 24, 2014, Ford Motor Company (Ford) announced that the Company plans to release its April 2014 sales results on May 1, 2014 at 9:30 a.m. ET. Following the result release, at 10:30 a.m. ET, the Company's U.S. Sales Analyst Erich Merkle will hold a conference call with investment community and news media to discuss the monthly sales numbers and related market trends. In addition, John Felice, Ford Vice President, U.S. Marketing, Sales and Service, and Emily Kolinski Morris, Ford's senior U.S. economist will participate in the call. The full analyst notes on Ford are available to download free of charge at:

http://www.analystsreview.com/1751-F-29Apr2014.pdf

--
Mead Johnson Nutrition Company Analyst Notes
On April 24, 2014, Mead Johnson Nutrition Company (Mead Johnson) released its Q1 2014 earnings. The Company reported Q1 2014 net sales of $1.1 billion, up 7.3% YoY. During the quarter, the Company's net sales from Asia segment improved 6.9% YoY to $592.7 million. The Company's North America/Europe segment sales grew 9.1% YoY to $308.2 million, led by an expansion in the children's nutrition business, non-Women, Infants and Children market share gains and retailer inventory adjustments. The Company's Q1 2014 net earnings attributable to shareholders came in at $202.4 million or $1.00 per diluted share, compared to net income of $188.0 million or $0.92 per diluted share in Q1 2013. For full-year 2014, the Company expects non-GAAP diluted EPS in the range of $3.60 to $3.72. The full analyst notes on Mead Johnson are available to download free of charge at:

http://www.analystsreview.com/1751-MJN-29Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review